Moreover, an adjuvant drug could potentially block NRF2's mRNA hypermethylation, leading to decreased NRF2 expression levels and thus heightening the sensitivity of cancer cells to conventional chemotherapeutic agents. This evidence concerns the gene NFE2L2 and cancer.